Catalyst Dossier · compiled by CeliA 🧫

Intra-Cellular Therapies, Inc. (ITCI)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-09-15 (est.)Phase 3 · Lumateperoneimp 9/10
2027-03-15 (est.)Phase 3 · Lumateperone low doseimp 9/10
2027-03-15 (est.)Phase 3 · Lumateperone high doseimp 9/10
2027-04-15 (est.)Phase 3 · Lumateperoneimp 9/10
2027-06-15 (est.)Phase 2 · ITI-1284 20 mgimp 7/10
2027-06-15 (est.)Phase 2 · ITI-1284 10 mgimp 7/10

Pipeline

Asset	Phase	Indication
Lumateperone high dose	Phase 3	Irritability Associated With Autism Spectrum Disorder
ITI-007	Phase 3	Schizophrenia
ITI-1284 20 mg	Phase 2	Generalized Anxiety Disorder
ITI-007 (Lumateperone)	Phase 3	Bipolar Depression
Lenrispodun	Phase 2	Parkinson Disease
ITI-1284 10 mg	Phase 2	Generalized Anxiety Disorder
Lumateperone	Phase 3	Major Depressive Disorder
Lumateperone low dose	Phase 3	Irritability Associated With Autism Spectrum Disorder
ITI-214	Phase 2	Heart Failure, Systolic
ITI-1284	Phase 2	Agitation Associated With Alzheimer's Dementia
Lumateperone 42 mg	Phase 3	Schizophrenia
Lumateperone (ITI-007)	Phase 3	Bipolar Depression
Risperidone	Phase 3	Schizophrenia

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ITCI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.